SCHEMBL3605752

SCHEMBL3605752

Cc1c(C)c2c(c(C)c1NC(=O)CC(C)(C)C)C(c1ccccc1)C(C)(C)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
KCNQ2 O43526 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
ADORA1 P30542 1/20 0.34
MAOB P27338 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
POLB P06746 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 2/20 0.32
NR1I2 O75469 1/20 0.31
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601766 0.89 KCNQ2 (0.36) HPGDMAPTRAB9AGAAALDH1A1
SCHEMBL3604067 0.89 HPGD (0.38) HPGDMAPTRAB9AGAAALDH1A1
SCHEMBL3613015 0.89 KCNQ2 (0.36) HPGDMAPTRAB9AGAAALDH1A1
SCHEMBL3609776 0.88 KCNQ2 (0.35) HPGDMAPTALDH1A1KDM4EKCNQ2
SCHEMBL3590239 0.88 KCNQ2 (0.35) HPGDGAAALDH1A1KDM4EKCNQ2
SCHEMBL3602429 0.86 CACNA1F (0.36) HPGDRAB9AGAAALDH1A1KDM4E
SCHEMBL3590985 0.85 KDM4E (0.37) HPGDMAPTRAB9AGAAALDH1A1
SCHEMBL3606335 0.83 KCNQ2 (0.35) HPGDMAPTALDH1A1KDM4EKCNQ2
SCHEMBL3598907 0.83 SMN1; SMN2 (0.42) HPGDMAPTRAB9AGAAALDH1A1
SCHEMBL3598768 0.80 KCNQ2 (0.39) HPGDMAPTRAB9AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637527-B1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL (JP) 2013-04-17 EP disclosed
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-23 US disclosed
US-7507841-B2 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-24 US disclosed
US-20090023800-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-01-22 US disclosed
US-7465815-B2 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-16 US disclosed
US-20080021087-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-01-24 US disclosed
US-20070099990-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 US disclosed
EP-1637527-A1 CANNABINOID RECEPTOR MODULATOR Takeda Pharmaceutical Company Limited (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR CNR1, CNR2, GPR18 HPGD 1416/4885MAPT 4392/4885RAB9A 631/4885
US-20080021087-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 HPGD 1416/4885MAPT 4392/4885RAB9A 631/4885
US-20090023800-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 HPGD 1416/4885MAPT 4392/4885RAB9A 631/4885
US-20070099990-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 HPGD 1416/4885MAPT 4392/4885RAB9A 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.